Literature DB >> 18596628

Antibiotic resistance--what's dosing got to do with it?

Jason A Roberts1, Peter Kruger, David L Paterson, Jeffrey Lipman.   

Abstract

OBJECTIVE: This review seeks to identify original research articles that link antibiotic dosing and the development of antibiotic resistance for different antibiotic classes. Using this data, we seek to apply pharmacodynamic principles to assist clinical practice for suppressing the emergence of resistance. Concepts such as mutant selection window and mutant prevention concentration will be discussed. DATA SOURCES: PubMed, EMBASE, and the Cochrane Controlled Trial Register. STUDY SELECTION: All articles that related antibiotic doses and exposure to the formation of antibiotic resistance were reviewed. DATA SYNTHESIS: The escalation of antibiotic resistance continues worldwide, most prominently in patients in intensive care units. Data are emerging from in vitro and in vivo studies that suggest that inappropriately low antibiotic dosing may be contributing to the increasing rate of antibiotic resistance. Fluoroquinolones have widely been researched and publications on other antibiotic classes are emerging. Developing dosing regimens that adhere to pharmacodynamic principles and maximize antibiotic exposure is essential to reduce the increasing rate of antibiotic resistance.
CONCLUSIONS: Antibiotic dosing must aim to address not only the bacteria isolated, but also the most resistant subpopulation in the colony, to prevent the advent of further resistant infections because of the inadvertent selection pressure of current dosing regimens. This may be achieved by maximizing antibiotic exposure by administering the highest recommended dose to the patient.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18596628     DOI: 10.1097/CCM.0b013e318180fe62

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  84 in total

1.  Therapeutic drug monitoring of antimicrobials.

Authors:  Jason A Roberts; Ross Norris; David L Paterson; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2012-01       Impact factor: 4.335

2.  Fluoroquinolone Resistance in Salmonella and the Utility of Pefloxacin Disk Diffusion [corrected].

Authors:  Ferric C Fang
Journal:  J Clin Microbiol       Date:  2015-08-26       Impact factor: 5.948

3.  Refugia and the evolutionary epidemiology of drug resistance.

Authors:  Andrew W Park; James Haven; Ray Kaplan; Sylvain Gandon
Journal:  Biol Lett       Date:  2015-11       Impact factor: 3.703

Review 4.  Changing the pill: developments toward the promise of an ultra-long-acting gastroretentive dosage form.

Authors:  David H Altreuter; Ameya R Kirtane; Tyler Grant; Cecilia Kruger; Giovanni Traverso; Andrew M Bellinger
Journal:  Expert Opin Drug Deliv       Date:  2018-11-13       Impact factor: 6.648

5.  Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model.

Authors:  Phillip J Bergen; Jürgen B Bulitta; Carl M J Kirkpatrick; Kate E Rogers; Megan J McGregor; Steven C Wallis; David L Paterson; Roger L Nation; Jeffrey Lipman; Jason A Roberts; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

6.  Population Pharmacokinetics and Target Attainment of Cefepime in Critically Ill Patients and Guidance for Initial Dosing.

Authors:  Mohammad H Al-Shaer; Michael N Neely; Jiajun Liu; Kartikeya Cherabuddi; Veena Venugopalan; Nathaniel J Rhodes; Kenneth Klinker; Marc H Scheetz; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

Review 7.  Augmented renal clearance: implications for antibacterial dosing in the critically ill.

Authors:  Andrew A Udy; Jason A Roberts; Robert J Boots; David L Paterson; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

8.  Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥40 kg/m(2)) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring.

Authors:  Manjunath P Pai; Piergiorgio Cojutti; Federico Pea
Journal:  Clin Pharmacokinet       Date:  2014-08       Impact factor: 6.447

9.  Population Pharmacokinetics of Piperacillin following Continuous Infusion in Critically Ill Patients and Impact of Renal Function on Target Attainment.

Authors:  Vibeke Klastrup; Anders Thorsted; Merete Storgaard; Steffen Christensen; Lena E Friberg; Kristina Öbrink-Hansen
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

10.  Optimal drug synergy in antimicrobial treatments.

Authors:  Joseph Peter Torella; Remy Chait; Roy Kishony
Journal:  PLoS Comput Biol       Date:  2010-06-03       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.